Clinical Trial

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Here, the investigators present the results from a Phase Ib/II study of PM8002 in combination with nab-paclitaxel in subjects with locally advanced or metastatic triple negative breast cancer without previous systematic treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-06-15; most recent amendment 2025-03-09.
Status change: Recruiting → Active, Not Recruiting 2025-03-09
Trial Details
NCT Number NCT05918133
Lead Sponsor Biotheus Inc.
Conditions TNBC
Enrollment 42 participants
Start Date 2022-07-01
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-11